The first AI platform to solve cancer vaccine failure
Oncocine engineers personalised mRNA cancer vaccines in under 2 hours. The industry takes 4 to 12 weeks and fails 90% of the time.
Scroll
The problem
Cancer vaccines keep failing. Every time. Here is why.
90%
Failure rate of cancer therapeutics
£2.9B
Cost per drug to market
You are a pharma or biotech professional. Your cancer vaccine trial just failed. It almost always does because of four compounding failures. Click each link to see where it breaks.
01
Antigen selection
Wrong targets
02
Tumour microenvironment (TME)
Immune cells blocked
03
Delivery and platform
Antigens degrade
04
Clinical trial design
Wrong patients
Select a link above
Where does your trial fail?
Click each chain link to see exactly where the industry breaks down and how Oncocine re-engineers it.
Validation
Validated against peer-reviewed clinical data.
33 patients
3 cancer types
3 published peer-reviewed datasets
Melanoma · Colorectal · Triple-negative breast cancer
Sahin et al. Nature 2017 · Wood et al. Cancer Research 2023 · Aparicio et al. Frontiers in Immunology 2022
Market opportunity
The fastest growing segment in pharma
TAM
$443BGlobal cancer immunotherapy11.9% CAGR
SAM
$38.5BPersonalised vaccines and neoantigen discovery44.9% CAGR
SOM
$770M to $1.93B2 to 5% market share by year 5
Why we are the right people to build this
The team
IM
Ishani Malhotra
CEO and Founder
Serial biotech founder in oncology with a successful track record. CRUK Woman Entrepreneur 2024. Built Carcinotech to $6M. TME modelling expertise. Multiple cancer biotech patents.
AC
Alan Clark
Chief Scientific Officer
25 years oncology drug discovery. Organon, Alere, TC BioPharm. TME specialist. Clinical trial expertise in cancer immunotherapy.
MM
Michal Magid-Slav
Fractional CTO
20 years AI and ML in pharma. Ex-Director, GSK Translational Omics. Multi-omics pipelines at scale.
Dr Ross Cagan
Scientific Advisor
Regius Professor of Precision Medicine, University of Glasgow. Co-founded Medros and Raer Therapeutics. Wohl Fellow, Royal Society.
Dr Antje Walz
Scientific Advisor
Founder, tkc suisse. Ex-Roche senior leadership. 20 years translational drug development. PK/PD and clinical pharmacology.
The raise
£2.5M
Pre-seed · SAFE / ASA or priced round
Join us in building the infrastructure for the next generation of cancer treatments.
From sample to vaccine. Faster, smarter, personalised.
Oncocine's mission is to develop immunotherapeutics for cancer patients faster, smarter and personalised.
